SCHEMBL1633570

SCHEMBL1633570

Clc1ccc(OC2CNC2)c2nc(Nc3ccc(N4CCOCC4)cc3)ncc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.50
CDK1 P06493 3/20 0.50
CDK4 P11802 3/20 0.50
CCNB1 P14635 3/20 0.50
CCND1 P24385 3/20 0.50
CCNE1 P24864 3/20 0.50
JAK2 O60674 2/20 0.47
TBK1 Q9UHD2 2/20 0.47
LRRK2 Q5S007 2/20 0.47
WEE1 P30291 1/20 0.47
EGFR P00533 1/20 0.47
CCNK O75909 1/20 0.46
CCNA2 P20248 1/20 0.46
CCND3 P30281 1/20 0.46
CDK9 P50750 1/20 0.46
CDK6 Q00534 1/20 0.46
SYK P43405 1/20 0.46
PKMYT1 Q99640 2/20 0.46
INSR P06213 2/20 0.46
IGF1R P08069 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634274 0.91 CDK4 (0.51) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL13498315 0.90 JAK2 (0.51) CDK2CCNE1JAK2TBK1LRRK2
SCHEMBL1634818 0.90 SYK (0.47) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL1632896 0.87 MAPK9 (0.49) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL1634301 0.86 LRRK2 (0.55) JAK2LRRK2PTK2MAPK10
SCHEMBL1633182 0.82 JAK2 (0.54) CDK2CCNE1JAK2TBK1CCNA2
SCHEMBL1633410 0.81 SYK (0.52) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL1633304 0.81 CCNT1 (0.45) CDK2CDK1CCNB1LRRK2CCNA2
SCHEMBL1632890 0.80 CDK2 (0.51) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL1633643 0.80 CDK4 (0.51) CDK2CDK1CDK4CCNB1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed